CN120168498A - 治疗化疗难治性癌症的新联合用药方案 - Google Patents

治疗化疗难治性癌症的新联合用药方案 Download PDF

Info

Publication number
CN120168498A
CN120168498A CN202510203958.9A CN202510203958A CN120168498A CN 120168498 A CN120168498 A CN 120168498A CN 202510203958 A CN202510203958 A CN 202510203958A CN 120168498 A CN120168498 A CN 120168498A
Authority
CN
China
Prior art keywords
cancer
formula
compound
pharmaceutically acceptable
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202510203958.9A
Other languages
English (en)
Chinese (zh)
Inventor
李嘉强
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
1Globe Biomedical Co Ltd
Original Assignee
1Globe Biomedical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 1Globe Biomedical Co Ltd filed Critical 1Globe Biomedical Co Ltd
Publication of CN120168498A publication Critical patent/CN120168498A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202510203958.9A 2018-10-12 2019-10-12 治疗化疗难治性癌症的新联合用药方案 Pending CN120168498A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2018111952393 2018-10-12
CN201811195239 2018-10-12
CN201980066957.7A CN113164438B (zh) 2018-10-12 2019-10-12 治疗化疗难治性癌症的新联合用药方案
PCT/CN2019/110904 WO2020074010A1 (zh) 2018-10-12 2019-10-12 治疗化疗难治性癌症的新联合用药方案

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201980066957.7A Division CN113164438B (zh) 2018-10-12 2019-10-12 治疗化疗难治性癌症的新联合用药方案

Publications (1)

Publication Number Publication Date
CN120168498A true CN120168498A (zh) 2025-06-20

Family

ID=70163618

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202510203958.9A Pending CN120168498A (zh) 2018-10-12 2019-10-12 治疗化疗难治性癌症的新联合用药方案
CN201980066957.7A Active CN113164438B (zh) 2018-10-12 2019-10-12 治疗化疗难治性癌症的新联合用药方案

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201980066957.7A Active CN113164438B (zh) 2018-10-12 2019-10-12 治疗化疗难治性癌症的新联合用药方案

Country Status (15)

Country Link
US (2) US12257227B2 (https=)
EP (1) EP3865130A4 (https=)
JP (2) JP7513286B2 (https=)
CN (2) CN120168498A (https=)
AU (1) AU2019357933B2 (https=)
BR (1) BR112021006898A2 (https=)
CA (1) CA3115869A1 (https=)
EA (1) EA202190771A1 (https=)
IL (1) IL282228A (https=)
MX (1) MX2021004151A (https=)
PH (1) PH12021550815A1 (https=)
SG (1) SG11202103707TA (https=)
TW (1) TWI848990B (https=)
WO (1) WO2020074010A1 (https=)
ZA (1) ZA202102494B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3865130A4 (en) * 2018-10-12 2022-07-20 1Globe Biomedical Co., Ltd. NEW COMBINATION SOLUTION FOR THE TREATMENT OF CHEMOTHERAPY-REFRACTORY CANCER

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3050566B1 (en) 2007-09-10 2018-11-28 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
EP2547205B1 (en) 2010-03-19 2024-03-20 1Globe Biomedical Co., Ltd. Novel methods for targeting cancer stem cells
RU2571661C2 (ru) 2010-03-19 2015-12-20 Бостон Байомедикал, Инк. Новые соединения и композиции для нацеливания на злокачественные стволовые клетки
US9150530B2 (en) 2011-03-04 2015-10-06 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. Esters of 4, 9-dihydroxy-naphtho [2, 3-b] furans for disease therapies
WO2013166618A1 (en) 2012-05-08 2013-11-14 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE
EP2983790A2 (en) * 2013-04-09 2016-02-17 Boston Biomedical, Inc. Methods for treating cancer
US20180085341A1 (en) 2015-04-17 2018-03-29 Boston Biomedical, Inc. Methods for treating cancer
WO2017132049A1 (en) * 2016-01-20 2017-08-03 Boston Biomedical, Inc. Methods for treating cancer
CN107766371B (zh) * 2016-08-19 2023-11-17 中兴通讯股份有限公司 一种文本信息分类方法及其装置
EP3865130A4 (en) * 2018-10-12 2022-07-20 1Globe Biomedical Co., Ltd. NEW COMBINATION SOLUTION FOR THE TREATMENT OF CHEMOTHERAPY-REFRACTORY CANCER

Also Published As

Publication number Publication date
US20250235425A1 (en) 2025-07-24
CN113164438B (zh) 2025-03-18
PH12021550815A1 (en) 2021-10-04
JP7513286B2 (ja) 2024-07-09
JP2024123152A (ja) 2024-09-10
JP2022504760A (ja) 2022-01-13
AU2019357933A1 (en) 2021-05-20
EP3865130A1 (en) 2021-08-18
MX2021004151A (es) 2021-09-08
BR112021006898A2 (pt) 2021-07-20
EA202190771A1 (ru) 2021-09-07
CA3115869A1 (en) 2020-04-16
EP3865130A4 (en) 2022-07-20
IL282228A (en) 2021-05-31
SG11202103707TA (en) 2021-05-28
AU2019357933B2 (en) 2023-11-23
US12257227B2 (en) 2025-03-25
US20210393571A1 (en) 2021-12-23
TW202027738A (zh) 2020-08-01
KR20210076951A (ko) 2021-06-24
TWI848990B (zh) 2024-07-21
WO2020074010A1 (zh) 2020-04-16
ZA202102494B (en) 2023-01-25
CN113164438A (zh) 2021-07-23

Similar Documents

Publication Publication Date Title
US20180085341A1 (en) Methods for treating cancer
US20190224157A1 (en) Methods for treating cancer
US10646464B2 (en) Methods for treating cancer
US20190231735A1 (en) Methods for treating cancer
US20250235425A1 (en) New Combination Solution for Treating Chemotherapy Refractory Cancer
US20180098959A1 (en) Methods for treating cancer
HK40047114A (en) New combination solution for treating chemotherapy refractory cancer
HK40124738A (zh) 治疗化疗难治性癌症的新联合用药方案
KR102960038B1 (ko) 화학요법 불응성 암을 치료하기 위한 신규한 조합 방안
HK40048413A (en) New combination solution for treating chemotherapy refractory cancer
EA046190B1 (ru) Новое комбинированное решение для лечения рака, резистентного к химиотерапии

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40124738

Country of ref document: HK